Primary Progressive Multiple Sclerosis (PPMS): Pipeline Intelligence, 2019

Report ID: CmaxInsight 853 | Number of pages: 80 | Publish Date: Jun 2019 | Publisher: CmaxInsight | Category: Lifesciences and Healthcare
This report can be delivered to the clients within 1-2 Business Days.

CmaxInsight’s, “Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this Indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Primary Progressive Multiple Sclerosis (PPMS). 
Highlights and Scope of the Report 
Indication Overview:
This section of the report provides comprehensive coverage of indication enables the client to understand the landscape of the Primary Progressive Multiple Sclerosis (PPMS). It covers the basic definition, causes, symptoms, pathophysiology and treatment guidelines for Primary Progressive Multiple Sclerosis (PPMS) disease. The section highlights the symptoms experienced by the patients, and disease progression in patients. The report also summarizes the multiple methods through which the patient can be diagnosed for Primary Progressive Multiple Sclerosis (PPMS) disease. 
Pipeline Covered:
This section mentions all the promising therapies in different phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. The section also details the products which have been dormant or discontinued during the trial stages of development.
Drug Profiles:
The pipeline guide features provide descriptive drug profiles for the pipeline products which comprise product description, Research and development, and product development activity.
• Product description
It comprises of descriptive drug profiles for the pipeline products in terms of its mechanism of action, mode of administration, molecule type, chemical information, etc.
• Research and development 
This section of the report focusing on the clinical and pre-clinical activity which provide detailed information about the efficacy, safety and tolerability of pipeline drugs. A snapshot on the clinical trial of a pipeline therapy includes information about sponsor, stage of development, trial design, enrollment number, location, study start and primary completion date, and dosage frequency and formulation of the drug.
• Product Development Activity
This section of the report provides detail information about licensing and collaboration, funding & financing, designation, patent, technology, key milestones and other developmental activities.
Therapeutic assessment 
The report comprises of comparative pipeline therapeutics assessment by stage of development, therapy type, target, molecule type, and route of administration across this indication.
Company profile 
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Methodology
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by CmaxInsight’s team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases. 
Reasons to buy
• Establish a comprehensive understanding of key competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Discover in licensing and out licensing strategies by identifying potential partners with progressing projects for Primary Progressive Multiple Sclerosis (PPMS) to enhance and expand business potential and scope
• Plan mergers and acquisitions successfully by identifying major players with the most promising pipeline therapeutics in the target demographic
• Our extensive in-depth analysis on therapy portfolio support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the dormant or discontinued drugs
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Assess challenges and opportunities that influence Primary Progressive Multiple Sclerosis (PPMS) R&D 
Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

1. Report Introduction
• Executive Summary
• Key findings 
2. Primary Progressive Multiple Sclerosis (PPMS)– Disease Overview
3. Pipeline Therapeutics
• An Overview of Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS)      
4. Comparative Analysis of Pipeline Therapeutics
5. Products in Last / Mid / Early Clinical Stage Development
5.1 Drug Name: Company Name
• Product Description
• Research and Development (Clinical and Pre-clinical activity)
• Product Development Activities
• Key Development milestone 
6. Products in Pre-clinical Stage Development 
6.1 Drug Name: Company Name
• Product Description
• Research and Development (Pre-clinical activity)
• Product Development Activities
• Key Development milestone 
7. Products in Discovery Stage Development
7.1 Drug Name: Company Name
• Product Description
• Research and Development (In-vitro activity)
• Product Development Activities
• Key Development milestone
8. Therapeutic Assessment of Pipeline Active Products
• Pipeline Assessment by Route of Administration
• Pipeline Assessment by Stage and Route of Administration 
• Pipeline Assessment by Molecule Type
• Pipeline Assessment by Stage and Molecule Type
• Pipeline Assessment by Indication
9. Dormant / Discontinued Products
9.1 Drug Name: Company Name
• Product Description 
• Research and Development 
• Product Development Activities
• Reason for dormancy/discontinuation
10. Company Profiling 
Appendix
Report Methodology
Disclaimer
About CmaxInsight
Note: Certain sections of the table of contents would vary according to the availability of information
Table 1: Total Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS)
Table 2: Number of Products under Development by Companies
Table 3: Late stage Therapeutic Products 
Table 4: Mid stage Therapeutic Products 
Table 5: Early stage Therapeutic Products 
Table 6: Pre-clinical stage Therapeutic Products 
Table 7: Discovery stage Therapeutic Products 
Table 8: Pipeline Analysis by Route of Administration
Table 9: Pipeline Analysis by Stage and Route of Administration
Table 10: Pipeline Analysis by Molecule Type
Table 11: Pipeline Analysis by Stage and Molecule Type
Table 12: Pipeline Analysis by Target
Table 13: Dormant / Discontinued Products
Table 14: Company Profile
Figure 1: Total Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS)
Figure 2: Late stage Therapeutic Products
Figure 3: Mid stage Therapeutic Products 
Figure 4: Early stage Therapeutic Products 
Figure 5: Pre-clinical stage Therapeutic Products 
Figure 6: Discovery stage Therapeutic Products 
Figure 7: Pipeline Analysis by Route of Administration
Figure 8: Pipeline Analysis by Stage and Route of Administration
Figure 9: Pipeline Analysis by Molecule Type
Figure 10: Pipeline Analysis by Stage and Molecule Type
Figure 11: Pipeline Analysis by Target
Figure 12: Dormant / Discontinued Products
This free Sample Report is purely a representation of our full report, for evaluating the market scope/data and make informed purchase decisions.